0.5–5 × 107 DCs/m2 transfected with 5 g RNA/ 106 DCs intravenously and 0.5 × 107 DCs/m2 intradermally, 3 times biweekly with escalating dose, 3 times at 3-month intervals.
0.5–5 × 107 DCs/m2 transfected with 5 g RNA/106 DCs intravenously and 0.5 × 107 DCs/m2 intradermally, 3 times biweekly with excalating dose, 3 times at 3-month intervals.
Arm 1: 107 DCs electroporated with 5 g RNA/106 DCs intradermally, 3 times biweekly, 18 g/kg DAB389 IL-2 prior to vaccination. Arm 2: 107 DCs electroporated with 5 g RNA/106 DCs intradermally, 3 times biweekly.
Arm 1: 107 DCs electroporated with 1 g hTERT RNA/106 DCs intradermally, 3 (6 patients) or 6 (5 patients) times weekly. Arm 2: 107 DCs electroporated with 1 g LAMP hTERT RNA/106 DCs intradermally, 3 (6 patients) or 6 (3 patients) times weekly.